What is Range Biotechnologies?
Founded in 2022 and headquartered in San Francisco, California, Range Biotechnologies operates at the intersection of advanced proteomics and data-driven biotechnology. The company is dedicated to unlocking complex biological insights through high-throughput analysis, aiming to revolutionize how researchers approach drug discovery and personalized medicine. By leveraging sophisticated engineering and computational biology, Range Biotechnologies seeks to address critical bottlenecks in the current therapeutic development pipeline, positioning itself as a vital infrastructure provider for the modern biopharma ecosystem.
How much funding has Range Biotechnologies raised?
Range Biotechnologies has raised a total of $5.2M across 1 funding round:
Angel/Seed
$5.2M
Angel/Seed (2023): $5.2M with participation from Artis Ventures Management Iii, Pear VC, Civilization Ventures, and Page One Ventures
Key Investors in Range Biotechnologies
Artis Ventures Management Iii
Artis Ventures is a dedicated venture capital fund focused on Tech Bio+Health, investing in innovative data-driven life sciences companies that aim to enhance human health and wellness.
Pear VC
Pear VC specializes in pre-seed and seed investments, partnering with founders at the earliest stages to develop innovative companies through talent recruitment and go-to-market support.
Civilization Ventures
Civilization Ventures is a venture capital firm that invests in innovative companies within the health tech and biopharma sectors, focusing on preventative, personalized, and regenerative healthcare solutions.
What's next for Range Biotechnologies?
With the successful closure of this major strategic investment, Range Biotechnologies is poised to scale its proteomics platform to meet increasing enterprise-level demand. The company's roadmap likely includes the expansion of its laboratory infrastructure, the recruitment of specialized talent in bioinformatics and molecular biology, and the establishment of key partnerships with pharmaceutical entities. As the firm continues to mature, the focus will shift toward demonstrating the clinical utility of its platform, potentially setting the stage for future commercialization milestones and further institutional financing rounds to support long-term growth objectives.
See full Range Biotechnologies company page
